More Bleeding Linked To Rivaroxaban In Observational Study

–Compared to dabigatran, rivaroxaban was associated with more intracranial and other serious bleeds. A new observational study finds that patients who take rivaroxaban (Xarelto, Johnson & Johnson) may be more likely to have serious bleeding events than patients who take dabigatran (Pradaxa, Boehringer Ingelheim). In a paper published in JAMA Internal Medicine, David Graham and...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Heart Rhythms People, Places & Events Policy & Ethics dabigatran NOAC Observational study Pradaxa rivaroxaban Xarelto Source Type: blogs